Insulin resistance metabolomic profile in non-diabetic women with systemic lupus erythematosus
Patients with systemic lupus erythematosus (SLE) have a higher prevalence of insulin resistance (IR) and metabolic syndrome (MetS) than controls. To evaluate IR in non-diabetic women with SLE by means of biomarkers using high-throughput metabolomic techniques. Cross-sectional study in patients with...
Gespeichert in:
Veröffentlicht in: | Gaceta médica de México 2021, Vol.157 (6), p.594-598 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Patients with systemic lupus erythematosus (SLE) have a higher prevalence of insulin resistance (IR) and metabolic syndrome (MetS) than controls.
To evaluate IR in non-diabetic women with SLE by means of biomarkers using high-throughput metabolomic techniques.
Cross-sectional study in patients with SLE. A metabolomic approach was employed using ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry. MetS was evaluated according to NCEP-ATP III criteria.
Seventy patients with SLE were included, out of whom 45 (64.2%) and 27 (38.5%) had IR and MetS, respectively. Patients with IR had a higher body mass index and hypertension more often than those without IR. Chronic damage and disease activity were not related to IR. A Quantose-IR score ≥ 63 was more common in patients with MetS (81.5 vs. 53.5%; p = 0.02). Quantose-IR score was also correlated with the number of criteria for MetS (r: 0.35; p = 0.003).
In non-diabetic women with SLE, the prevalence of IR based on Quantose-IR score was 64.2%. |
---|---|
ISSN: | 0016-3813 |
DOI: | 10.24875/GMM.M21000622 |